Nanomerics - Pharmaceutical Nanotechnology

Nanomerics is "switching on" drugs. Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current drugs to develop products that deliver patient benefit in areas of unmet medical need.

Meet Nanomerics at APS PharSci 2015

Nanomerics CEO Prof A. Schatzlein will be presenting latest results of the development of MET nano-enabled therapies at the annual APS PharmSci Meeting.
The conference, the 6th of this series, will be held from the 6th 7th - 9th September 2015, at the East Midlands Conference Centre, Nottingham at Nottingham.
Prof Schatzlein will be presenting in the BSNM Nanomedicines and Biotherapeutics session.

Meet Nanomerics at BIO 2015

BIO logo

Meet Nanomerics at BIO 2015. As part of London's delegation Nanomerics will be visiting this year's conference in Philadelphia from June 15-18th. ​ Nanomerics will be attending BIO and the BIO One-on-One Partnering. Get in touch to meet us: here.

Nanomerics strengthens scientific advisory board

Eye open font awesomeNanomerics is delighted to announce the appointment of Professor John Dart to its Scientific Advisory Board.  Professor Dart is a key opinion leader and world leading ophthalmologist who holds appointments at Moorfields Hospital London, UK and University College London, UK who will support clinical development of Nanomerics' ophthalmology pipeline.

Nanomerics' Oral Amphotericin B Promises Better Treatment for Millions has developed a nano-enabled orally active form of Amphotericin B which could provide improved access to efficacious therapy to millions of people affected by Leishmaniasis.

Nanomerics Announces Completion of Major Preclinical Toxicology Programme on its Molecular Envelope Technology

Nanomerics today announced the successful completion of a major preclinical toxicology programme on its Molecular Envelope Technology (MET), paving the way for the technology’s clinical testing.  Safety pharmacology, mutagenicity and a range of 28 day repeat dose Good Laboratory Practice (GLP) standard toxicology tests have been completed on two species (rodent and non-rodent).

Fighting Fit - Nanomerics featured in CBI Business Voice Publication

moleculesIn the October edition of the CBI's  online publication 'Business Voice' journalist Dan Jellinek looks at how leading UK innovators contribute to the expanding UK life science sector. Nanomerics' CEO Prof Andreas Schatzlein describes how support from the EPSRC,  the Wellcome Trust, and Innovate UK has helped Nanomerics to translate scientific research into medicines which bring important patient benefits.

Prof Martin Koltzenburg Joins Nanomerics Advisory Board

Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.  Professor Koltzenburg’s appointment will  support the clinical development of iNanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.

Antibodies to the Brain - A High Impact Collaboration

Nanomerics is embarking on a new EPSRC funded collaborative research project with the Danish pharmaceutical company H Lundbeck, UCL, and Exeter University.  

LogosAs part of the new collaboration, the company aims to develop new and exciting ways to deliver antibodies to the brain, building on the molecular envelope technology Nanomerics has developed to deliver previously undeliverable drugs to the organ.

UCL’s School of Life and Medical Sciences Celebrates Enterprise Successes

UCL Enterprise publicationSpin-out Nanomerics and its founders were highlighted in UCL’s School of Life and Medical Sciences recently launched  'Enterprise' publication. The brochure, available here, celebrates recent success stories of translation of scientific knowledge. 

MET Fibrous Hydrogel
MET Fibrous Hydrogel
Subscribe to Nanomerics RSS